超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

美國BioVascular Inc
BioVascular公司是一家私人持股公司，開發(fā)生物技術(shù)藥物和設(shè)備的控制內(nèi)膜增生與血管有關(guān)的程序和控制的危險因素與心血管發(fā)病率和死亡率。BioVascular的主導(dǎo)產(chǎn)品， saratin ，是一種多肽生產(chǎn)中酵母重組手段。該產(chǎn)品是授權(quán)默克制藥公司于2005年。 BioVascular開始人體臨床試驗的saratin血液透析移植準(zhǔn)入和在2006年年底將開始人體試驗治療周圍動脈移植在2007年年初。

BioVascular的第二個產(chǎn)品利用了一種新型機(jī)制，減少了最近界定心血管危險因素。該產(chǎn)品將進(jìn)入人體試驗階段在2007年年中。
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality.

BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007.

BioVascular’s second product utilizes a novel mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.